Condition
Squamous Cell Carcinoma of the Cervix
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed3
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03357757Phase 2Completed
Avelumab With Valproic Acid in Virus-associated Cancer
NCT03894618Phase 1Completed
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
NCT03221400Phase 1Unknown
PEN-866 in Patients With Advanced Solid Malignancies
NCT01639625Phase 2CompletedPrimary
Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
NCT02042885Phase 1Terminated
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Showing all 5 trials